NT PHARMA (01011) released its interim results, reporting a loss attributable to shareholders of 18.433 million yuan, an increase of 9.03% compared to the same period last year.

NT PHARMA (01011) released its mid-term results for 2026, reporting revenues of 23.665 million yuan, an increase of 97.29% year-on-year; the loss attributable to shareholders amounted to 18.433 million yuan, a year-on-year increase of 9.03%; with a loss per share of 2.24 cents. Currently, the Group has established a multidimensional collaborative business matrix: the core treatment segment focuses on the specialized distribution and marketing of the orthopedic innovative drug "Teriparatide," supplemented by distinctive traditional Chinese medicine and health products for bone health, forming a solid business foundation. On this basis, the Group strategically expanded its diagnostic services by acquiring the artificial intelligence bone health diagnostic company Siasun Robot & Automation. These intelligent devices utilize AI algorithms to achieve efficient and accurate screening for bone density and bone health risks, filling the business gap in early screening for bone health.